Health and Healthcare
Amgen, Finally Some Good News (AMGN, MRK)
Published:
Last Updated:
Shares of Amgen Inc. (NASDAQ: AMGN) are seeing a small gain in after-hours trading.
The troubled biotech giant announced that findings from its head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). This study was a one-year non-pivotal Phase III study and it demonstrated superior results for the primary and all secondary endpoints.
The primary endpoint was in the total hip and it was listed as 80% greater in the group. This was a twice-yearly subcutaneous injection in a double-blind group of 504 women who suffered from low BMD.
FOSAMAX is an osteoporosis drug from Merck & Co. (NYSE: MRK).
Jon C. Ogg
May 19, 2008
Jon Ogg produces and edits the "10 Stocks Under $10" newsletter and he does not own securities in the companies he covers.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.